Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H15N3O2 |
Molecular Weight | 269.2985 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(N)C=CC=C2
InChI
InChIKey=VAZAPHZUAVEOMC-UHFFFAOYSA-N
InChI=1S/C15H15N3O2/c1-10(19)17-12-8-6-11(7-9-12)15(20)18-14-5-3-2-4-13(14)16/h2-9H,16H2,1H3,(H,17,19)(H,18,20)
Molecular Formula | C15H15N3O2 |
Molecular Weight | 269.2985 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/17018703Curator's Comment: description was created based on several sources, including:
http://adisinsight.springer.com/drugs/800002525
http://en.pharmacodia.com/web/drug/1_1986.html
http://www.apexbt.com/ci994-tacedinaline.html
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17018703
Curator's Comment: description was created based on several sources, including:
http://adisinsight.springer.com/drugs/800002525
http://en.pharmacodia.com/web/drug/1_1986.html
http://www.apexbt.com/ci994-tacedinaline.html
A second generation of HDACs, synthetic benzamide-containing HDACs such as Tacedinaline (CI-994), have reached phase I and II clinical trials. It has been investigated for its applications to the treatment of cancers such as Breast cancer and Colorectal cancer. Tacedinaline has been in phase III clinical trials by Pfizer for the treatment of advanced non-small cell lung cancer and pancreatic cancer combined with gemcitabine. However, this research has been discontinued. Mechanism of Action: Angiogenesis inhibitors; Histone deacetylase inhibitors. Pharmacokinetics showed that CI-994 absorption and disposition were unaffected by carboplatin and paclitaxel coadministration.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL325 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24780082 |
0.045 nM [IC50] | ||
Target ID: CHEMBL1937 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24780082 |
0.031 nM [IC50] | ||
Target ID: CHEMBL1829 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24780082 |
0.02 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts. | 2008 Mar 15 |
|
Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL. | 2011 Oct |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16641168
6 mg/m(2)/day during 21 days
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8319208
The half-dose once daily treatment with Acetyldinaline (11.85 mg/kg) for 1 or 2 cycles resulted in about a 4.5 or > 8-log leukemic cell kill, respectively.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:40:22 GMT 2023
by
admin
on
Fri Dec 15 15:40:22 GMT 2023
|
Record UNII |
UMF554N5FG
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1946
Created by
admin on Fri Dec 15 15:40:22 GMT 2023 , Edited by admin on Fri Dec 15 15:40:22 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2746
Created by
admin on Fri Dec 15 15:40:22 GMT 2023 , Edited by admin on Fri Dec 15 15:40:22 GMT 2023
|
PRIMARY | |||
|
100000155280
Created by
admin on Fri Dec 15 15:40:22 GMT 2023 , Edited by admin on Fri Dec 15 15:40:22 GMT 2023
|
PRIMARY | |||
|
UMF554N5FG
Created by
admin on Fri Dec 15 15:40:22 GMT 2023 , Edited by admin on Fri Dec 15 15:40:22 GMT 2023
|
PRIMARY | |||
|
DB12291
Created by
admin on Fri Dec 15 15:40:22 GMT 2023 , Edited by admin on Fri Dec 15 15:40:22 GMT 2023
|
PRIMARY | |||
|
NN-16
Created by
admin on Fri Dec 15 15:40:22 GMT 2023 , Edited by admin on Fri Dec 15 15:40:22 GMT 2023
|
PRIMARY | |||
|
112522-64-2
Created by
admin on Fri Dec 15 15:40:22 GMT 2023 , Edited by admin on Fri Dec 15 15:40:22 GMT 2023
|
PRIMARY | |||
|
CHEMBL235191
Created by
admin on Fri Dec 15 15:40:22 GMT 2023 , Edited by admin on Fri Dec 15 15:40:22 GMT 2023
|
PRIMARY | |||
|
90195
Created by
admin on Fri Dec 15 15:40:22 GMT 2023 , Edited by admin on Fri Dec 15 15:40:22 GMT 2023
|
PRIMARY | |||
|
8328
Created by
admin on Fri Dec 15 15:40:22 GMT 2023 , Edited by admin on Fri Dec 15 15:40:22 GMT 2023
|
PRIMARY | |||
|
SUB129288
Created by
admin on Fri Dec 15 15:40:22 GMT 2023 , Edited by admin on Fri Dec 15 15:40:22 GMT 2023
|
PRIMARY | |||
|
DTXSID60150095
Created by
admin on Fri Dec 15 15:40:22 GMT 2023 , Edited by admin on Fri Dec 15 15:40:22 GMT 2023
|
PRIMARY | |||
|
C2202
Created by
admin on Fri Dec 15 15:40:22 GMT 2023 , Edited by admin on Fri Dec 15 15:40:22 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
IC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|